Hippocratic AI, a Palo Alto startup building generative AI agents for healthcare, has closed a $126 million Series C at a $3.5 billion valuation, the company announced on November 3, 2025. The round was led by Avenir Growth Capital and brings total funding to $404 million, according to the announcement.
What does a Series C actually buy?
A Series C is a late-stage round: by this point a company is expected to be commercializing at scale, not proving its technology works. The documented record here fits that pattern. In the company's announcement, Hippocratic AI reports more than 50 health system, payor and pharma clients across six countries, over 1,000 built clinical use cases, and more than 115 million completed patient interactions with no reported safety incidents, all company-claimed figures.
The buyer list matters as much as the size. The round included not only financial investors such as CapitalG, General Catalyst, Andreessen Horowitz and Kleiner Perkins, but also Universal Health Services and Cincinnati Children's Hospital Medical Center, institutions that also operate as customers. Strategic capital from customers is a recurring feature of healthcare Series C rounds, because it ties the investor's return to products it already deploys inside its own hospitals and clinics.
How is the $126 million structured?
The announcement describes a priced primary round: $126 million of new equity sold at an agreed $3.5 billion valuation, led by one growth investor with existing backers participating. That is the standard shape of a Series C, in contrast to the convertible notes and safe agreements that dominate seed stages. Priced rounds set a per-share price, which fixes exactly how much existing ownership the new money dilutes in exchange for the capital.
Per round coverage at Pulse 2.0, the company said the capital is earmarked for product development, international expansion and strategic mergers and acquisitions. An M&A line item in a Series C use of funds signals a company planning to buy capabilities or customer bases rather than only build them organically. Further detail on the allocation between those buckets was not disclosed, so the split remains company-claimed and unspecified.
Why does this round matter for the market?
The round is a data point in the competition to automate patient access and clinical staffing, a market where labor shortages are documented across health systems in multiple countries. The valuation step also shows where late-stage investors currently price demonstrable adoption: a company with 15 months of commercial operations and reported nine-figure interaction volumes commanded $3.5 billion, per the announcement, a figure that is announced and company-claimed rather than independently verified.
For buyers, the practical consequence is that safety-focused agent products will keep arriving from well-funded vendors, and procurement teams will increasingly compare them on documented evidence of clinical safety rather than on demonstration quality. The company's zero-safety-incident claim is self-reported, and verifying such claims through pilot data and reference customers remains the buyer's work before any contract is signed.
